These innovative compounds represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://dawudbaql568331.tokka-blog.com/39512467/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide